Batu Biologics Strategy for FDA Approval of Lung Cancer Immunotherapy Featured in San Diego Business Journal
The donation-based crowdfunding campaign provides non-dilutive capital to the company which accelerates our ongoing preclinical lung cancer immunological experiments needed for FDA IND submission.
Batu Biologics’ Lung Cancer Immunotherapy Featured in CEOCFO Magazine
Anti-Angiogenesis Lung Cancer Vaccine Discussed as Potential “Next Generation” Non-Toxic Therapy
Given that the majority of lung cancers are diagnosed late in progression, the majority of patients have limited treatment options, which often carry a heavy burden of toxicity.
Batu Biologics Reaches 50% of Crowdfunding Goal
Lung Cancer Vaccine Company Leverages Online Donations to Fund Preclinical Research
We are enthusiastic at the flurry of support, which we attribute in part to the joining of UCSD cancer vaccine expert Dr. Boris Minev and industry veteran Dr. Alan Lewis to our scientific advisory board.
Batu Biologics Appoints Biotechnology Industry Veteran, Dr. Alan Lewis, to Scientific Advisory Board
Former CEO of Medistem to Assist in the FDA Development of the First Anti-Angiogenic Cancer Vaccine for Lung Cancer
The Batu Biologics Team is extremely excited to have Dr. Alan Lewis on board to assist with the development and commercialization of ValloVax™.
